Events
Founded as Genetix PharmaceuticalsJesse Gelsinger Dies, Interest Lost in Gene TherapySeries A Financing, $20 million raisedPhase I/II Beta Thallassemia trial launchedGenetix Launches ADL ProgramSeries B, $35 million raised, new CEO from Third Rock VenturesSeries C, $35 millionSeries D, $60 millionInitial Public Offering, $116 millionCash assets expected to run outPhase 3 End Date, Beta ThalassemiaPhase 2/3 end date, ALD
Comments